Mortality and morbidity in relation to changes in albuminuria, glucose status and systolic blood pressure: an analysis of the ONTARGET and TRANSCEND studies

Diabetologia

Volumn 57, Issue 10, 2014, Pages 2019-2029

  Schmieder, Roland E ^a   Schutte, Rudolph ^b   Schumacher, Helmut ^c   Böhm, Michael ^d   Mancia, Giuseppe ^e   Weber, Michael A ^f   McQueen, Matthew ^g   Teo, Koon ^g   Yusuf, Salim ^g  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b NORTH WEST UNIVERSITY   (South Africa)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^d SAARLAND UNIVERSITY   (Germany)

^e SAN GERARDO HOSPITAL   (Italy)

^f SUNY Downstate Medical Center   (United States)

^g MCMASTER UNIVERSITY   (Canada)

Author keywords

Albuminuria; Cardiovascular disease; Change; Prognosis

Indexed keywords

GLUCOSE; PLACEBO; RAMIPRIL; TELMISARTAN; GLUCOSE BLOOD LEVEL;

AGED; ALBUMINURIA; ARTICLE; CARDIOVASCULAR MORTALITY; COHORT ANALYSIS; CONTROLLED STUDY; DETERIORATION; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; URINALYSIS; BLOOD; BLOOD PRESSURE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSPECTIVE STUDY;

AGED; ALBUMINURIA; BLOOD GLUCOSE; BLOOD PRESSURE; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 84926610786     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-014-3330-9     Document Type: Article

References (44)

1. Orasanu G, Plutzky J (2009) The pathologic continuum of diabetic vascular disease. J Am Coll Cardiol 53: S35-S42.
2. Laing SP, Swerdlow AJ, Slater SD et al (2003) Mortality from heart disease in a cohort of 23, 000 patients with insulin-treated diabetes. Diabetologia 46: 760-765.
3. Matheus AS, Tannus LR, Cobas RA, Palma CC, Negrato CA, Gomes MB (2013) Impact of diabetes on cardiovascular disease: an update. Int J Hypertens 2013: 653789.
4. Fox CS, Coady S, Sorlie PD et al (2004) Trends in cardiovascular complications of diabetes. JAMA 292: 2495-2499.
5. Stehouwer CD, Nauta JJ, Zeldenrust GC, Hackeng WH, Donker AJ, den Ottolander GJ (1992) Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet 340: 319-323.
6. Ninomiya T, Perkovic V, de Galan BE et al (2009) Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 20: 1813-1821.
7. Targher G, Zoppini G, ChoncholMet al (2011) Glomerular filtration rate, albuminuria and risk of cardiovascular and all-cause mortality in type 2 diabetic individuals. Nutr Metab Cardiovasc Dis 21: 294-301.
8. Sarnak MJ, Astor BC (2011) Implications of proteinuria: CKD progression and cardiovascular outcomes. Adv Chronic Kidney Dis 18: 258-266.
9. Astor BC, Matsushita K, Gansevoort RTet al (2011) Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int 79: 1331-1340.
10. Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE (2008) Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients with left ventricular hypertrophy and diabetes. J Nephrol 21: 566-569.
11. Schrader J, Lüders S, Kulschewski A, MARPLE Study Group et al (2006) Microalbuminuria and tubular proteinuria as risk predictors of cardiovascular morbidity and mortality in essential hypertension: final results of a prospective long-term study (MARPLE Study). J Hypertens 24: 541-548.
12. Usui T, Ninomiya T, Nagata M, Doi Y, Hata J, Fukuhara M, Kiyohara Y (2011) Albuminuria as a risk factor for peripheral arterial disease in a general population: the Hisayama study. J Atheroscler Thromb 18: 705-712.
13. Vlek AL, van der Graaf Y, SpieringW, Algra A, Visseren FL (2008) Cardiovascular events and all-cause mortality by albuminuria and decreased glomerular filtration rate in patients with vascular disease. J Intern Med 264: 351-360.
14. Hillege HL, Fidler V, Diercks GF, Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group et al (2002) Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 106: 1777-1782.
15. Konta T, Kudo K, Sato H et al (2013) Albuminuria is an independent predictor of all-cause and cardiovascular mortality in the Japanese population: the Takahata study. Clin Exp Nephrol 17: 805-810.
16. Schmieder RE, Mann JF, Schumacher H et al (2011) Changes in albuminuria predict mortality and morbidity in patients with vascular disease. J Am Soc Nephrol 22: 1353-1364.
17. Spoelstra-de Man AM, Brouwer CB, Stehouwer CD, Smulders YM (2001) Rapid progression of albumin excretion is an independent predictor of cardiovascular mortality in patients with type 2 diabetes and microalbuminuria. Diabetes Care 24: 2097-2101.
18. Yuyun MF, Dinneen SF, Edwards OM, Wood E, Wareham NJ (2003) Absolute level and rate of change of albuminuria over 1 year independently predictmortality and cardiovascular events in patients with diabetic nephropathy. Diabet Med 20: 277-282.
19. Zandbergen AA, Vogt L, de Zeeuw D et al (2007) Change in albuminuria is predictive of cardiovascular outcome in normotensive patients with type 2 diabetes and microalbuminuria. Diabetes Care 30: 3119-3121.
20. Estacio RO, Dale RA, Schrier R, Krantz MJ (2012) Relation of reduction in urinary albumin excretion to ten-year cardiovascular mortality in patients with type 2 diabetes and systemic hypertension. Am J Cardiol 109: 1743-1748.
21. De Zeeuw D, Remuzzi G, Parving HH et al (2004) Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 110: 921-927.
22. Teo K, Yusuf S, Sleight P et al (2004) Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J 148: 52-61.
23. Yusuf S, Teo K, Anderson C et al (2008) Effects of the angiotensinreceptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 372: 1174-1183.
24. Yusuf S, Teo KK, Pogue J et al (2008) Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358: 1547-1559.
25. Barzilay JI, Gao P, Ryden L et al (2011) Effects of telmisartan on glucose levels in people at high risk for cardiovascular disease but free fromdiabetes: the TRANSCENDstudy. Diabetes Care 34: 1902-1907.
26. Mann JF, Schmieder RE, McQueen M et al (2008) Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 372: 547-553.
27. Levey AS, Stevens LA, Schmid CH, CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150: 604-612.
28. Vuong QH (1989) Likelihood ratio tests for model selection and nonnested hypotheses. Econometrica 57: 307-333.
29. Schmieder RE, Schrader J, ZidekWet al (2007) Low-grade albuminuria and cardiovascular risk: what is the evidence? Clin Res Cardiol 96: 247-257.
30. Klausen K, Borch-Johnsen K, Feldt-Rasmussen B et al (2004) Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation 110: 32-35.
31. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342: 145-153.
32. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288: 2981-2997.
33. WhitingDR, Guariguata L, Weil C, Shaw J (2011) IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 94: 311-321.
34. Redon J, Mancia G, Sleight P et al (2012) Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial). J Am Coll Cardiol 59: 74-83.
35. Danaei G, Singh GM, Paciorek CJ et al (2013) The global cardiovascular risk transition: associations of four metabolic risk factors with national income, urbanization, and Western diet in 1980 and 2008. Circulation 127: 1493-1498.
36. Meigs JB (2010) Epidemiology of type 2 diabetes and cardiovascular disease: translation from population to prevention: the Kelly West award lecture 2009. Diabetes Care 33: 1865-1871.
37. Stehouwer CD, Smulders YM (2006) Microalbuminuria and risk for cardiovascular disease: analysis of potential mechanisms. J Am Soc Nephrol 17: 2106-2111.
38. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A (1989) Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia 32: 219-226.
39. Viberti G, Wheeldon NM (2002) Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressureindependent effect. Circulation 106: 672-678.
40. Blacklock CL, Hirst JA, TaylorKS, Stevens RJ, RobertsNW, Farmer AJ (2011) Evidence for a dose effect of renin-angiotensin system inhibition on progression of microalbuminuria in type 2 diabetes: a meta-analysis. Diabet Med 28: 1182-1187.
41. Mancia G, Fagard R, Narkiewicz K et al (2013) 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 31: 1281-1357.
42. Gansevoort RT, Verhave JC, Hillege HL et al; PREVEND Study Group (2005) The validity of screening based on spot morning urine samples to detect subjects with microalbuminuria in the general population. Kidney Int Suppl: S28-S35.
43. Viana LV, Gross JL, Camargo JL, Zelmanovitz T, da Costa Rocha EP, Azevedo MJ (2012) Prediction of cardiovascular events, diabetic nephropathy, and mortality by albumin concentration in a spot urine sample in patients with type 2 diabetes. J Diabetes Complicat 26: 407-412.
44. Justesen TI, Petersen JL, Ekbom P, Damm P, Mathiesen ER (2006) Albumin-to-creatinine ratio in random urine samples might replace 24-h urine collections in screening for micro-and macroalbuminuria in pregnant woman with type 1 diabetes. Diabetes Care 29: 924-925.